期刊文献+

泮托拉唑钠联合甲磺酸加贝酯治疗急性胰腺炎42例

The Effect of Pantoprazole Sodium Combined with Gabexate Mesylate on the Levels of Biochemical Indexes and Inflammatory Factors in Patients with Acute Pancreatitis
下载PDF
导出
摘要 目的:探讨泮托拉唑钠联合甲磺酸加贝酯在急性胰腺炎(AP)患者中的应用效果。方法:选取2019年6月至2020年6月于上饶卫生学校附属医院诊治的84例AP患者,依照随机数字表法分成两组,各42例。对照组采用甲磺酸加贝酯治疗,观察组加用泮托拉唑钠联合治疗,连续用药7 d。对比两组临床疗效、生化指标、炎症因子水平、不良反应。结果:观察组治疗总有效率为95.24%,高于对照组的80.95%,差异有统计学意义(P<0.05);治疗前,两组血尿素氮(BUN)、尿淀粉酶(UAMY)、血淀粉酶(AMY)和肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平相比,差异无统计学意义(P>0.05);治疗后,观察组BUN、UAMY、AMY和TNF-α、IL-6水平低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率相比,差异无统计学意义(P>0.05)。结论:泮托拉唑钠联合甲磺酸加贝酯治疗AP效果确切,改善患者生化指标和炎症因子水平,加快症状缓解,安全性较高,值得推广。 Objective:To investigate the effect of pantoprazole sodium combined with gabexate mesylate in patients with acute pancreatitis(AP).Methods:A total of 84 AP patients diagnosed and treated in the Affiliated Hospital of Shangrao Health School from June 2019 to June 2020 were selected and divided into two groups according to the random number table method,with 42 cases in each group.The control group was treated with gabexate mesylate,and the observation group was treated with pantoprazole sodium for 7 consecutive days.The clinical efficacy,biochemical indicators,inflammatory factor levels,and adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was 95.24%,which was higher than 80.95%in the control group.The difference was statistically significant(P<0.05).Before treatment,the two groups blood urea nitrogen(BUN),urine amylase(UAMY),blood amylase(AMY),tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6),there was no significant difference(P>0.05);after treatment,the observation group BUN,UAMY,AMY,TNF-αand IL-6 were lower than those of the control group,and the difference was statistically significant(P<0.05);there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Pantoprazole sodium combined with gabexate mesylate has a definite effect in the treatment of AP.It can improve the patient's biochemical indicators and inflammatory factor levels,speed up symptom relief,and is safe.It is worthy of promotion.
作者 夏丽 XIA Li(Shangrao Health School,Shangrao Jiangxi 334600,China)
机构地区 上饶卫生学校
出处 《药品评价》 CAS 2021年第11期674-676,共3页 Drug Evaluation
关键词 胰腺炎 泮托拉唑钠 甲磺酸加贝酯 临床疗效 炎症因子 Pancreatitis Pantoprazole sodium Gabexate mesylate Clinical efficacy Inflammatory factors
  • 相关文献

参考文献9

二级参考文献84

共引文献157

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部